Log in

NASDAQ:IMAB - Phoenix Tree Stock Price, Forecast & News

$13.40
-0.42 (-3.04 %)
(As of 02/27/2020 03:55 AM ET)
Today's Range
$13.02
Now: $13.40
$14.49
50-Day Range N/A
52-Week Range
$9.30
Now: $13.40
$15.79
Volume71,758 shs
Average Volume178,437 shs
Market Capitalization$764.60 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for immuno-oncology; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMAB
CUSIPN/A
CIKN/A
Phone86-21-6057-8000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees185
Market Cap$764.60 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAB and its competitors with MarketBeat's FREE daily newsletter.


Phoenix Tree (NASDAQ:IMAB) Frequently Asked Questions

What is Phoenix Tree's stock symbol?

Phoenix Tree trades on the NASDAQ under the ticker symbol "IMAB."

What price target have analysts set for IMAB?

3 Wall Street analysts have issued 1 year price targets for Phoenix Tree's stock. Their forecasts range from $16.00 to $18.09. On average, they anticipate Phoenix Tree's stock price to reach $17.34 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price. View Analyst Price Targets for Phoenix Tree.

What is the consensus analysts' recommendation for Phoenix Tree?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Phoenix Tree in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Phoenix Tree.

Has Phoenix Tree been receiving favorable news coverage?

Media stories about IMAB stock have been trending negative this week, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Phoenix Tree earned a daily sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Phoenix Tree.

Who are some of Phoenix Tree's key competitors?

What other stocks do shareholders of Phoenix Tree own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Phoenix Tree investors own include NVIDIA (NVDA), Full House Resorts (FLL) and EXACT Sciences (EXAS).

Who are Phoenix Tree's key executives?

Phoenix Tree's management team includes the folowing people:
  • Dr. Joan Huaqiong Shen M.D., Ph.D., CEO & Director (Age 57)
  • Dr. Zheru Zhang Ph.D., Pres & Director (Age 56)
  • Dr. Jingwu Zhang Zang M.D., Ph.D., Founder, Honorary Chairman & Director (Age 63)
  • Mr. Jielun Zhu, CFO & Director (Age 43)
  • Dr. Lili Qian Ph.D., VP of Operations (Age 37)

When did Phoenix Tree IPO?

(IMAB) raised $100 million in an initial public offering on Thursday, January 16th 2020. The company issued 7,400,000 shares at $12.00-$15.00 per share. Jefferies and CICC acted as the underwriters for the IPO and China Renaissance and Huatai Securities (USA) were co-managers.

When did the company's quiet period expire?

Phoenix Tree's quiet period expired on Wednesday, February 26th. Phoenix Tree had issued 7,407,400 shares in its initial public offering on January 17th. The total size of the offering was $103,703,600 based on an initial share price of $14.00. During the company's quiet period, insiders and underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Phoenix Tree?

Shares of IMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Phoenix Tree's stock price today?

One share of IMAB stock can currently be purchased for approximately $13.40.

How big of a company is Phoenix Tree?

Phoenix Tree has a market capitalization of $764.60 million. Phoenix Tree employs 185 workers across the globe.View Additional Information About Phoenix Tree.

What is Phoenix Tree's official website?

The official website for Phoenix Tree is http://www.i-mabbiopharma.com/.

How can I contact Phoenix Tree?

Phoenix Tree's mailing address is SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6057-8000 or via email at [email protected]


MarketBeat Community Rating for Phoenix Tree (NASDAQ IMAB)

Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  5 (Vote Outperform)
Underperform Votes:  1 (Vote Underperform)
Total Votes:  6
MarketBeat's community ratings are surveys of what our community members think about Phoenix Tree and other stocks. Vote "Outperform" if you believe IMAB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMAB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel